Expedition Therapeutics

Summary active Updated Aug 5, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location San Francisco, California
Founded 2024
Latest Stage Series B
Total Raised $115M+ (Series B)
Sector
biotech healthcare therapeutics respiratory

Investors

Venrock series-b (2026)

Founders

Yi Larson CEO

About

Expedition Therapeutics is a biopharmaceutical company launched in 2024 that is developing next-generation therapies for respiratory disease, led by CEO Yi Larson 13. Its lead program, EXPD-101, is a next-generation DPP1 inhibitor being evaluated in a Phase 2 clinical trial for chronic obstructive pulmonary disease (COPD), designed to target neutrophilic inflammation 12. The company operates via a China NewCo model that in-licenses drug candidates originally developed in China 3.

Funding History

Date Round Amount Lead Co-investors
2026-08-05 Series B $115M General Atlantic RA Capital, Vivo Capital, Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma, Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners, Venrock Healthcare Capital Partners 12

The oversubscribed Series B will fund advancement of EXPD-101 through Phase 2 development 12. Brett Zbar, a managing director at General Atlantic, will join Expedition’s board of directors 1.

What Investors Say

No independently sourced investor testimonials found beyond the press release.

What Founders Say

No independently sourced founder testimonials found.

Sources

  1. General Atlantic, “Expedition Therapeutics Announces Oversubscribed $115 Million Series B Financing to Advance Next-Generation DPP1 Inhibitor for COPD,” August 5, 2026, accessed August 2026. https://www.generalatlantic.com/media-article/expedition-therapeutics-announces-oversubscribed-115-million-series-b-financing-to-advance-next-generation-dpp1-inhibitor-for-copd/↩↩↩↩↩

  2. BioPharma Dive, “A COPD drug from China draws $115M in venture funding,” August 5, 2026, accessed August 2026. https://www.biopharmadive.com/news/expedition-therapeutics-series-b-dpp1-copd-general-atlantic/826874/↩↩↩

  3. Endpoints News, “Expedition gets another $115M for its twist on China NewCo model,” August 5, 2026, accessed August 2026. https://endpoints.news/expedition-gets-another-115m-for-its-twist-on-china-newco-model/↩↩